p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1‐NF‐κB pathway in human ovarian cancer cells

Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctiona...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Sci
Main Authors: Yan, Xiao‐Yu, Zhang, Yu, Zhang, Juan‐Juan, Zhang, Li‐Chao, Liu, Ya‐Nan, Wu, Yao, Xue, Ya‐Nan, Lu, Sheng‐Yao, Su, Jing, Sun, Lian‐Kun
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2017
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497928/
https://ncbi.nlm.nih.gov/pubmed/28498503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13276
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים